Annual report

Period2023-07-01 → 2024-06-30
Filed2024-09-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 145
MetricValuePeriodScopeSource row
Revenue¥5.2bn2023-07-01 → 2024-06-30Cons.Net sales
Revenue¥8.1bn2022-07-01 → 2023-06-30Cons.Net sales
Revenue¥9.3bn2021-07-01 → 2022-06-30dCons.Net sales (5-year summary)
Revenue¥8.9bn2020-07-01 → 2021-06-30dCons.Net sales (5-year summary)
Revenue¥9.3bn2019-07-01 → 2020-06-30dCons.Net sales (5-year summary)
Operating income−¥610m2023-07-01 → 2024-06-30Cons.Operating income
Operating income¥726m2022-07-01 → 2023-06-30Cons.Operating income
Ordinary income−¥566m2023-07-01 → 2024-06-30Cons.Ordinary income
Ordinary income¥727m2022-07-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥1.3bn2021-07-01 → 2022-06-30dCons.Ordinary income loss (5-year summary)
Ordinary income¥920m2020-07-01 → 2021-06-30dCons.Ordinary income loss (5-year summary)
Ordinary income¥1.1bn2019-07-01 → 2020-06-30dCons.Ordinary income loss (5-year summary)
Profit before tax−¥615m2023-07-01 → 2024-06-30Cons.Income before income taxes
Profit before tax¥725m2022-07-01 → 2023-06-30Cons.Income before income taxes
Net income (owners)−¥662m2023-07-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥452m2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥810m2021-07-01 → 2022-06-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥562m2020-07-01 → 2021-06-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥732m2019-07-01 → 2020-06-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥663m2023-07-01 → 2024-06-30Cons.Profit loss
Net income¥456m2022-07-01 → 2023-06-30Cons.Profit loss
Total assets¥6.9bnat 2024-06-30Cons.Assets
Total assets¥8.2bnat 2023-06-30Cons.Assets
Total assets¥8.5bnat 2022-06-30dCons.Total assets (5-year summary)
Total assets¥7.1bnat 2021-06-30dCons.Total assets (5-year summary)
Total assets¥7.4bnat 2020-06-30dCons.Total assets (5-year summary)
Total liabilities¥697mat 2024-06-30Cons.Liabilities
Total liabilities¥1.1bnat 2023-06-30Cons.Liabilities
Net assets / equity¥6.2bnat 2024-06-30Cons.Net assets
Net assets / equity¥7.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥6.8bnat 2022-06-30dCons.Net assets
Net assets / equity¥6.2bnat 2021-06-30dCons.Net assets (5-year summary)
Net assets / equity¥5.8bnat 2020-06-30dCons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2024-06-30Cons.Cash and deposits
Cash and deposits¥5.9bnat 2023-06-30Cons.Cash and deposits
Cash & equivalents¥4.8bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.9bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥6.0bnat 2022-06-30dCons.Cash and cash equivalents
Cash & equivalents¥4.3bnat 2021-06-30dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥4.5bnat 2020-06-30dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥881m2023-07-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥102m2022-07-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.1bn2021-07-01 → 2022-06-30dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥107m2020-07-01 → 2021-06-30dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥830m2019-07-01 → 2020-06-30dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥14m2023-07-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥160m2022-07-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥245m2021-07-01 → 2022-06-30dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥25m2020-07-01 → 2021-06-30dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥693m2019-07-01 → 2020-06-30dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥261m2023-07-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥130m2022-07-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥130m2021-07-01 → 2022-06-30dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥131m2020-07-01 → 2021-06-30dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥103m2019-07-01 → 2020-06-30dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-25.322023-07-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.272022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥30.952021-07-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.492020-07-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥27.972019-07-01 → 2020-06-30dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥238.28at 2024-06-30Cons.Net assets per share (5-year summary)
Net assets per share¥266.41at 2023-06-30Cons.Net assets per share (5-year summary)
Net assets per share¥254.14at 2022-06-30dCons.Net assets per share (5-year summary)
Net assets per share¥230.88at 2021-06-30dCons.Net assets per share (5-year summary)
Net assets per share¥214.39at 2020-06-30dCons.Net assets per share (5-year summary)
Equity ratio89.7%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio84.6%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio78.3%at 2022-06-30dCons.Equity to asset ratio (5-year summary)
Equity ratio84.5%at 2021-06-30dCons.Equity to asset ratio (5-year summary)
Equity ratio75.7%at 2020-06-30dCons.Equity to asset ratio (5-year summary)
ROE6.6%2022-07-01 → 2023-06-30Cons.Rate of return on equity (5-year summary)
ROE12.8%2021-07-01 → 2022-06-30dCons.Rate of return on equity (5-year summary)
ROE9.7%2020-07-01 → 2021-06-30dCons.Rate of return on equity (5-year summary)
ROE13.8%2019-07-01 → 2020-06-30dCons.Rate of return on equity (5-year summary)
Employees90at 2024-06-30Cons.Number of employees
Employees98at 2023-06-30Cons.Number of employees
Employees100at 2022-06-30dCons.Number of employees
Employees104at 2021-06-30dCons.Number of employees
Employees105at 2020-06-30dCons.Number of employees
Revenue¥304m2023-07-01 → 2024-06-30StandaloneNet sales
Revenue¥377m2022-07-01 → 2023-06-30StandaloneNet sales
Revenue¥439m2021-07-01 → 2022-06-30dStandaloneNet sales (5-year summary)
Revenue¥425m2020-07-01 → 2021-06-30dStandaloneNet sales (5-year summary)
Revenue¥425m2019-07-01 → 2020-06-30dStandaloneNet sales (5-year summary)
Operating income−¥6m2023-07-01 → 2024-06-30StandaloneOperating income
Operating income¥81m2022-07-01 → 2023-06-30StandaloneOperating income
Ordinary income¥2m2023-07-01 → 2024-06-30StandaloneOrdinary income
Ordinary income¥87m2022-07-01 → 2023-06-30StandaloneOrdinary income
Ordinary income¥137m2021-07-01 → 2022-06-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥132m2020-07-01 → 2021-06-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥116m2019-07-01 → 2020-06-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥9m2023-07-01 → 2024-06-30StandaloneIncome before income taxes
Profit before tax¥87m2022-07-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥10m2023-07-01 → 2024-06-30StandaloneProfit loss
Net income¥142m2022-07-01 → 2023-06-30StandaloneProfit loss
Net income¥195m2021-07-01 → 2022-06-30dStandaloneNet income loss (5-year summary)
Net income¥288m2020-07-01 → 2021-06-30dStandaloneNet income loss (5-year summary)
Net income¥155m2019-07-01 → 2020-06-30dStandaloneNet income loss (5-year summary)
Total assets¥4.2bnat 2024-06-30StandaloneAssets
Total assets¥4.3bnat 2023-06-30StandaloneAssets
Total assets¥4.5bnat 2022-06-30dStandaloneTotal assets (5-year summary)
Total assets¥4.2bnat 2021-06-30dStandaloneTotal assets (5-year summary)
Total assets¥4.1bnat 2020-06-30dStandaloneTotal assets (5-year summary)
Total liabilities¥29mat 2024-06-30StandaloneLiabilities
Total liabilities¥21mat 2023-06-30StandaloneLiabilities
Net assets / equity¥4.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥4.3bnat 2023-06-30StandaloneNet assets
Net assets / equity¥4.3bnat 2022-06-30dStandaloneNet assets
Net assets / equity¥4.2bnat 2021-06-30dStandaloneNet assets (5-year summary)
Net assets / equity¥4.1bnat 2020-06-30dStandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2024-06-30StandaloneCash and deposits
Cash and deposits¥1.3bnat 2023-06-30StandaloneCash and deposits
EPS (basic)¥-0.42023-07-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥5.442022-07-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥7.472021-07-01 → 2022-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥11.022020-07-01 → 2021-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥5.912019-07-01 → 2020-06-30dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥52022-07-01 → 2023-06-30StandaloneDividend paid per share (5-year summary)
Dividend per share¥52021-07-01 → 2022-06-30dStandaloneDividend paid per share (5-year summary)
Dividend per share¥52020-07-01 → 2021-06-30dStandaloneDividend paid per share (5-year summary)
Dividend per share¥52019-07-01 → 2020-06-30dStandaloneDividend paid per share (5-year summary)
Net assets per share¥158.55at 2024-06-30StandaloneNet assets per share (5-year summary)
Net assets per share¥163.95at 2023-06-30StandaloneNet assets per share (5-year summary)
Net assets per share¥163.52at 2022-06-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥161.05at 2021-06-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥155.03at 2020-06-30dStandaloneNet assets per share (5-year summary)
Equity ratio99.3%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio99.5%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio95.6%at 2022-06-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio99.5%at 2021-06-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio99.6%at 2020-06-30dStandaloneEquity to asset ratio (5-year summary)
ROE3.3%2022-07-01 → 2023-06-30StandaloneRate of return on equity (5-year summary)
ROE4.6%2021-07-01 → 2022-06-30dStandaloneRate of return on equity (5-year summary)
ROE7.0%2020-07-01 → 2021-06-30dStandaloneRate of return on equity (5-year summary)
ROE3.8%2019-07-01 → 2020-06-30dStandaloneRate of return on equity (5-year summary)
Shares issued26,158,200at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2023-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2022-06-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2021-06-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2020-06-30dStandaloneTotal number of issued shares (5-year summary)
Employees11at 2024-06-30StandaloneNumber of employees
Employees7at 2023-06-30StandaloneNumber of employees
Employees9at 2022-06-30dStandaloneNumber of employees
Employees8at 2021-06-30dStandaloneNumber of employees
Employees8at 2020-06-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 94
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2023-07-01 → 2024-06-30¥798,000
Reconciling Itemsreconcilingdepreciation2023-07-01 → 2024-06-30¥231,000
Reconciling Itemsreconcilingrevenue2023-07-01 → 2024-06-30−¥43m
Reconciling Itemsreconcilingrevenue external2023-07-01 → 2024-06-30¥2m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2024-06-30−¥44m
Reconciling Itemsreconcilingsegment assetsat 2024-06-30¥1.4bn
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2024-06-30−¥309m
Clinical Evidence Servicereportable segmentcapex2023-07-01 → 2024-06-30¥7m
Clinical Evidence Servicereportable segmentdepreciation2023-07-01 → 2024-06-30¥5m
Clinical Evidence Servicereportable segmentemployeesat 2024-06-3014 pure
Clinical Evidence Servicereportable segmentrevenue2023-07-01 → 2024-06-30¥236m
Clinical Evidence Servicereportable segmentrevenue external2023-07-01 → 2024-06-30¥221m
Clinical Evidence Servicereportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥15m
Clinical Evidence Servicereportable segmentsegment assetsat 2024-06-30¥298m
Clinical Evidence Servicereportable segmentsegment profit2023-07-01 → 2024-06-30−¥70m
Functional Cosmetic Retailingreportable segmentcapex2023-07-01 → 2024-06-30¥6m
Functional Cosmetic Retailingreportable segmentdepreciation2023-07-01 → 2024-06-30¥11m
Functional Cosmetic Retailingreportable segmentemployeesat 2024-06-3027 pure
Functional Cosmetic Retailingreportable segmentrevenue2023-07-01 → 2024-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentrevenue external2023-07-01 → 2024-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentsegment assetsat 2024-06-30¥2.6bn
Functional Cosmetic Retailingreportable segmentsegment profit2023-07-01 → 2024-06-30−¥153m
Functional Food Retailingreportable segmentcapex2023-07-01 → 2024-06-30¥310,000
Functional Food Retailingreportable segmentdepreciation2023-07-01 → 2024-06-30¥9m
Functional Food Retailingreportable segmentemployeesat 2024-06-3022 pure
Functional Food Retailingreportable segmentrevenue2023-07-01 → 2024-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue external2023-07-01 → 2024-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥10m
Functional Food Retailingreportable segmentsegment assetsat 2024-06-30¥1.0bn
Functional Food Retailingreportable segmentsegment profit2023-07-01 → 2024-06-30−¥158m
Functional Material Developmentreportable segmentdepreciation2023-07-01 → 2024-06-30¥928,000
Functional Material Developmentreportable segmentemployeesat 2024-06-307 pure
Functional Material Developmentreportable segmentrevenue2023-07-01 → 2024-06-30¥318m
Functional Material Developmentreportable segmentrevenue external2023-07-01 → 2024-06-30¥299m
Functional Material Developmentreportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥19m
Functional Material Developmentreportable segmentsegment assetsat 2024-06-30¥1.3bn
Functional Material Developmentreportable segmentsegment profit2023-07-01 → 2024-06-30−¥13m
Health Care Support Servicereportable segmentdepreciation2023-07-01 → 2024-06-30¥353,000
Health Care Support Servicereportable segmentemployeesat 2024-06-309 pure
Health Care Support Servicereportable segmentrevenue2023-07-01 → 2024-06-30¥595m
Health Care Support Servicereportable segmentrevenue external2023-07-01 → 2024-06-30¥595m
Health Care Support Servicereportable segmentsegment assetsat 2024-06-30¥382m
Health Care Support Servicereportable segmentsegment profit2023-07-01 → 2024-06-30¥93m
—segment totalcapex2023-07-01 → 2024-06-30¥13m
—segment totaldepreciation2023-07-01 → 2024-06-30¥27m
—segment totalrevenue2023-07-01 → 2024-06-30¥5.2bn
—segment totalrevenue external2023-07-01 → 2024-06-30¥5.2bn
—segment totalrevenue intersegment2023-07-01 → 2024-06-30¥44m
—segment totalsegment assetsat 2024-06-30¥5.6bn
—segment totalsegment profit2023-07-01 → 2024-06-30−¥301m
Reconciling Itemsreconcilingcapex2022-07-01 → 2023-06-30¥244,000
Reconciling Itemsreconcilingdepreciation2022-07-01 → 2023-06-30¥217,000
Reconciling Itemsreconcilingrevenue2022-07-01 → 2023-06-30−¥25m
Reconciling Itemsreconcilingrevenue external2022-07-01 → 2023-06-30¥2m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2023-06-30−¥26m
Reconciling Itemsreconcilingsegment assetsat 2023-06-30¥1.5bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2023-06-30−¥294m
Clinical Evidence Servicereportable segmentcapex2022-07-01 → 2023-06-30¥8m
Clinical Evidence Servicereportable segmentdepreciation2022-07-01 → 2023-06-30¥4m
Clinical Evidence Servicereportable segmentrevenue2022-07-01 → 2023-06-30¥617m
Clinical Evidence Servicereportable segmentrevenue external2022-07-01 → 2023-06-30¥602m
Clinical Evidence Servicereportable segmentrevenue intersegment2022-07-01 → 2023-06-30¥15m
Clinical Evidence Servicereportable segmentsegment assetsat 2023-06-30¥427m
Clinical Evidence Servicereportable segmentsegment profit2022-07-01 → 2023-06-30¥89m
Functional Cosmetic Retailingreportable segmentcapex2022-07-01 → 2023-06-30¥29m
Functional Cosmetic Retailingreportable segmentdepreciation2022-07-01 → 2023-06-30¥13m
Functional Cosmetic Retailingreportable segmentrevenue2022-07-01 → 2023-06-30¥3.9bn
Functional Cosmetic Retailingreportable segmentrevenue external2022-07-01 → 2023-06-30¥3.9bn
Functional Cosmetic Retailingreportable segmentsegment assetsat 2023-06-30¥3.3bn
Functional Cosmetic Retailingreportable segmentsegment profit2022-07-01 → 2023-06-30¥658m
Functional Food Retailingreportable segmentcapex2022-07-01 → 2023-06-30¥3m
Functional Food Retailingreportable segmentdepreciation2022-07-01 → 2023-06-30¥5m
Functional Food Retailingreportable segmentrevenue2022-07-01 → 2023-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue external2022-07-01 → 2023-06-30¥2.5bn
Functional Food Retailingreportable segmentsegment assetsat 2023-06-30¥1.3bn
Functional Food Retailingreportable segmentsegment profit2022-07-01 → 2023-06-30¥137m
Functional Material Developmentreportable segmentdepreciation2022-07-01 → 2023-06-30¥1m
Functional Material Developmentreportable segmentrevenue2022-07-01 → 2023-06-30¥501m
Functional Material Developmentreportable segmentrevenue external2022-07-01 → 2023-06-30¥490m
Functional Material Developmentreportable segmentrevenue intersegment2022-07-01 → 2023-06-30¥11m
Functional Material Developmentreportable segmentsegment assetsat 2023-06-30¥1.4bn
Functional Material Developmentreportable segmentsegment profit2022-07-01 → 2023-06-30¥43m
Health Care Support Servicereportable segmentdepreciation2022-07-01 → 2023-06-30¥935,000
Health Care Support Servicereportable segmentrevenue2022-07-01 → 2023-06-30¥553m
Health Care Support Servicereportable segmentrevenue external2022-07-01 → 2023-06-30¥553m
Health Care Support Servicereportable segmentsegment assetsat 2023-06-30¥315m
Health Care Support Servicereportable segmentsegment profit2022-07-01 → 2023-06-30¥93m
—segment totalcapex2022-07-01 → 2023-06-30¥39m
—segment totaldepreciation2022-07-01 → 2023-06-30¥25m
—segment totalrevenue2022-07-01 → 2023-06-30¥8.1bn
—segment totalrevenue external2022-07-01 → 2023-06-30¥8.1bn
—segment totalrevenue intersegment2022-07-01 → 2023-06-30¥26m
—segment totalsegment assetsat 2023-06-30¥6.8bn
—segment totalsegment profit2022-07-01 → 2023-06-30¥1.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,263
ItemContextValueUnit
Accounts receivable tradeCurrentYearInstant428934000JPY
Contract assetsPrior1YearInstant38348000JPY
Contract assetsCurrentYearInstant-JPY
Write downs of inventoriesPrior1YearDuration35250000JPY
Write downs of inventoriesCurrentYearDuration7903000JPY
Salaries and allowances sgaPrior1YearDuration484509000JPY
Salaries and allowances sgaCurrentYearDuration471661000JPY
Depreciation sgaPrior1YearDuration20872000JPY
Depreciation sgaCurrentYearDuration21310000JPY
Research and development expenses sgaPrior1YearDuration56337000JPY
Research and development expenses sgaCurrentYearDuration51467000JPY
Advertising expenses sgaPrior1YearDuration667268000JPY
Advertising expenses sgaCurrentYearDuration706252000JPY
Promotion expenses sgaPrior1YearDuration370649000JPY
Promotion expenses sgaCurrentYearDuration417933000JPY
Packing and transportation expenses sgaPrior1YearDuration341883000JPY
Packing and transportation expenses sgaCurrentYearDuration328685000JPY
Retirement benefit expenses sgaPrior1YearDuration20106000JPY
Retirement benefit expenses sgaCurrentYearDuration21025000JPY
Provision of allowance for doubtful accounts sgaPrior1YearDuration-4172000JPY
Provision of allowance for doubtful accounts sgaCurrentYearDuration108000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember601833000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E05367-000HealthCareSupportServiceReportableSegmentsMember552996000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember3943506000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalFoodRetailingReportableSegmentsMember2490546000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember489542000JPY
Revenues from external customersPrior1YearDuration_ReportableSegmentsMember8078426000JPY
Revenues from external customersPrior1YearDuration_ReconcilingItemsMember1500000JPY
Revenues from external customersPrior1YearDuration8079926000JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember15225000JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E05367-000HealthCareSupportServiceReportableSegmentsMember-JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember-JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalFoodRetailingReportableSegmentsMember-JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember11059000JPY
Transactions with other segmentsPrior1YearDuration_ReportableSegmentsMember26284000JPY
Transactions with other segmentsPrior1YearDuration_ReconcilingItemsMember-26284000JPY
Transactions with other segmentsPrior1YearDuration-JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember617058000JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E05367-000HealthCareSupportServiceReportableSegmentsMember552996000JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember3943506000JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalFoodRetailingReportableSegmentsMember2490546000JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember500602000JPY
Net salesPrior1YearDuration_ReportableSegmentsMember8104710000JPY
Net salesPrior1YearDuration_ReconcilingItemsMember-24784000JPY
Net salesPrior1YearDuration8079926000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember89068000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E05367-000HealthCareSupportServiceReportableSegmentsMember93270000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember657635000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalFoodRetailingReportableSegmentsMember137404000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember42595000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
balance sheet identitynon_consolidated 2023-06-30pass rounding
balance sheet identitynon_consolidated 2024-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net assetsnon_consolidated 2022-06-30pass
statement vs summary · net assetsnon_consolidated 2023-06-30pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2023-07-01/2024-06-30pass
statement vs summary · revenueconsolidated 2022-07-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-07-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2022-07-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2023-07-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2024-06-30pass
statement vs summary · total assetsnon_consolidated 2023-06-30pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass